Retrospective review of diphencyprone in the treatment of alopecia areata

R. C. Lamb, D. Young, S. Holmes

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Contact immunotherapy with diphencyprone (DCP) is used to treat alopecia areata (AA). Its reported efficacy is variable, and individual response cannot be predicted.  To identify patient and treatment course variables that may affect treatment outcome, and to review DCP service to identify potential areas for development and improvement.  This was a retrospective review of a DCP service over a 20-year period (1991–2010).  Complete data was available for 205 treatment courses, and 162 (79%) treatment courses were completed for 133 patients. Overall, 72.2% (96/133) of patients had some hair regrowth (any grade). In 15.8% of cases (21/133), response was > 90% regrowth. However, 27.1% (36/133) had no response. We found that extent of alopecia at baseline and duration of disease were statistically significant when comparing patients with an optimal outcome to those without (P < 0.05). In contrast to other reports, atopy, age at onset and nail dystrophy were not statistically significant. For patients receiving more than one course, response to DCP treatment was broadly consistent.  Extent of alopecia at baseline and duration of disease are important factors in predicting response. Our results suggest that atopy should not be considered a predictor of poor outcome with respect to DCP treatment. A need for improved data collection, particularly regarding longer-term outcomes, was identified. The role of maintenance therapy requires objective assessment. Opportunities for DCP self-administration by patients should be explored. Limitations of this study include the retrospective nature of the review and lack of long-term follow-up data.
LanguageEnglish
Number of pages7
JournalClinical and Experimental Dermatology
Early online date1 Dec 2015
DOIs
Publication statusE-pub ahead of print - 1 Dec 2015

Fingerprint

Alopecia Areata
Regrowth
Alopecia
Baseline
Therapeutics
Immunotherapy
Self Administration
Nails
Age of Onset
Hair
Therapy
diphenylcyclopropenone
Review
Efficacy
Predictors
Maintenance
Retrospective Studies
Contact
Term

Keywords

  • diphencyprone
  • alopecia areata
  • hair regrowth

Cite this

@article{3120f60c56294656a5a3bebd89005d07,
title = "Retrospective review of diphencyprone in the treatment of alopecia areata",
abstract = "Contact immunotherapy with diphencyprone (DCP) is used to treat alopecia areata (AA). Its reported efficacy is variable, and individual response cannot be predicted.  To identify patient and treatment course variables that may affect treatment outcome, and to review DCP service to identify potential areas for development and improvement.  This was a retrospective review of a DCP service over a 20-year period (1991–2010).  Complete data was available for 205 treatment courses, and 162 (79{\%}) treatment courses were completed for 133 patients. Overall, 72.2{\%} (96/133) of patients had some hair regrowth (any grade). In 15.8{\%} of cases (21/133), response was > 90{\%} regrowth. However, 27.1{\%} (36/133) had no response. We found that extent of alopecia at baseline and duration of disease were statistically significant when comparing patients with an optimal outcome to those without (P < 0.05). In contrast to other reports, atopy, age at onset and nail dystrophy were not statistically significant. For patients receiving more than one course, response to DCP treatment was broadly consistent.  Extent of alopecia at baseline and duration of disease are important factors in predicting response. Our results suggest that atopy should not be considered a predictor of poor outcome with respect to DCP treatment. A need for improved data collection, particularly regarding longer-term outcomes, was identified. The role of maintenance therapy requires objective assessment. Opportunities for DCP self-administration by patients should be explored. Limitations of this study include the retrospective nature of the review and lack of long-term follow-up data.",
keywords = "diphencyprone, alopecia areata, hair regrowth",
author = "Lamb, {R. C.} and D. Young and S. Holmes",
note = "{"}This is the peer reviewed version of the following article: Lamb, R. C., Young, D., & Holmes, S. (2015). Retrospective review of diphencyprone in the treatment of alopecia areata. Clinical and Experimental Dermatology., which has been published in final form at http://www.dx.doi.org/10.1111/ced.12776. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.{"}",
year = "2015",
month = "12",
day = "1",
doi = "10.1111/ced.12776",
language = "English",
journal = "Clinical and Experimental Dermatology",
issn = "0307-6938",

}

Retrospective review of diphencyprone in the treatment of alopecia areata. / Lamb, R. C.; Young, D.; Holmes, S.

In: Clinical and Experimental Dermatology, 01.12.2015.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Retrospective review of diphencyprone in the treatment of alopecia areata

AU - Lamb, R. C.

AU - Young, D.

AU - Holmes, S.

N1 - "This is the peer reviewed version of the following article: Lamb, R. C., Young, D., & Holmes, S. (2015). Retrospective review of diphencyprone in the treatment of alopecia areata. Clinical and Experimental Dermatology., which has been published in final form at http://www.dx.doi.org/10.1111/ced.12776. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving."

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Contact immunotherapy with diphencyprone (DCP) is used to treat alopecia areata (AA). Its reported efficacy is variable, and individual response cannot be predicted.  To identify patient and treatment course variables that may affect treatment outcome, and to review DCP service to identify potential areas for development and improvement.  This was a retrospective review of a DCP service over a 20-year period (1991–2010).  Complete data was available for 205 treatment courses, and 162 (79%) treatment courses were completed for 133 patients. Overall, 72.2% (96/133) of patients had some hair regrowth (any grade). In 15.8% of cases (21/133), response was > 90% regrowth. However, 27.1% (36/133) had no response. We found that extent of alopecia at baseline and duration of disease were statistically significant when comparing patients with an optimal outcome to those without (P < 0.05). In contrast to other reports, atopy, age at onset and nail dystrophy were not statistically significant. For patients receiving more than one course, response to DCP treatment was broadly consistent.  Extent of alopecia at baseline and duration of disease are important factors in predicting response. Our results suggest that atopy should not be considered a predictor of poor outcome with respect to DCP treatment. A need for improved data collection, particularly regarding longer-term outcomes, was identified. The role of maintenance therapy requires objective assessment. Opportunities for DCP self-administration by patients should be explored. Limitations of this study include the retrospective nature of the review and lack of long-term follow-up data.

AB - Contact immunotherapy with diphencyprone (DCP) is used to treat alopecia areata (AA). Its reported efficacy is variable, and individual response cannot be predicted.  To identify patient and treatment course variables that may affect treatment outcome, and to review DCP service to identify potential areas for development and improvement.  This was a retrospective review of a DCP service over a 20-year period (1991–2010).  Complete data was available for 205 treatment courses, and 162 (79%) treatment courses were completed for 133 patients. Overall, 72.2% (96/133) of patients had some hair regrowth (any grade). In 15.8% of cases (21/133), response was > 90% regrowth. However, 27.1% (36/133) had no response. We found that extent of alopecia at baseline and duration of disease were statistically significant when comparing patients with an optimal outcome to those without (P < 0.05). In contrast to other reports, atopy, age at onset and nail dystrophy were not statistically significant. For patients receiving more than one course, response to DCP treatment was broadly consistent.  Extent of alopecia at baseline and duration of disease are important factors in predicting response. Our results suggest that atopy should not be considered a predictor of poor outcome with respect to DCP treatment. A need for improved data collection, particularly regarding longer-term outcomes, was identified. The role of maintenance therapy requires objective assessment. Opportunities for DCP self-administration by patients should be explored. Limitations of this study include the retrospective nature of the review and lack of long-term follow-up data.

KW - diphencyprone

KW - alopecia areata

KW - hair regrowth

UR - http://onlinelibrary.wiley.com/doi/10.1111/ced.12776/abstract

U2 - 10.1111/ced.12776

DO - 10.1111/ced.12776

M3 - Article

JO - Clinical and Experimental Dermatology

T2 - Clinical and Experimental Dermatology

JF - Clinical and Experimental Dermatology

SN - 0307-6938

ER -